GMR
The Original

SMART BIOMEDICAL TECHNOLOGIES FOR PRECISION ONCOLOGY: ADVANCEMENTS IN CANCER DIAGNOSIS, MONITORING, AND PERSONALIZED THERAPEUTICS

Divya Amaravadi[1], Sudha Murugesan[2], Sadhana Kanukuntla[3], Nerella Mounika[4*]

[1]Research Scholar, Department of Pharmacy Practice, Saveetha College of Pharmaceutical Sciences, Saveetha Institute of Medical and Technical Sciences (SIMATS), Deemed University, Chennai, Tamil Nadu, India. ORCID ID: 0000-0001-9945-4501, Email ID: div4075@gmail.com
[2]Associate Professor, Department of Pharmacology, Saveetha College of Pharmaceutical Sciences, Saveetha Institute of Medical and Technical Sciences (SIMATS), Deemed University, Chennai, Tamil Nadu, India. ORCID ID: 0009-0003-2987-2531, Email ID: sudham.scop@saveetha.com
[3]Assistant Professor, School of Pharmacy, Anurag University, Hyderabad, Telangana-500088. ORCID ID: 0000-0002-7670-1941, Email ID: sadhanakanukuntla24@gmail.com
[4]Assistant Professor, School of Pharmacy, Anurag University, Hyderabad - 500 088, Telangana, India. ORCID ID: 0000-0002-4640-1462, Email ID: nmounikapharmacy@anurag.edu.in

ABSTRACT
Precision oncology has emerged as a transformative approach to cancer management by enabling personalized diagnosis, monitoring, and treatment based on individual molecular and clinical characteristics. Recent advancements in smart biomedical technologies have significantly accelerated this transition, providing innovative tools for improving the accuracy, efficiency, and effectiveness of cancer care. This review explores the role of emerging technologies, including artificial intelligence (AI), biosensors, wearable devices, nanotechnology, multi-omics platforms, digital health systems, and advanced computational analytics, in supporting precision oncology. The review discusses how AI-assisted imaging, liquid biopsies, molecular profiling, and smart biosensors have enhanced early cancer detection and diagnostic precision. It further examines the application of wearable sensors, digital biomarkers, remote monitoring systems, and real-time data analytics for continuous disease surveillance and treatment-response assessment. Additionally, the potential of smart drug delivery systems, targeted therapies, immunotherapies, gene-editing technologies, and predictive models in enabling personalized therapeutics is highlighted. The integration of these technologies into clinical oncology workflows through clinical decision support systems, digital health ecosystems, and multi-omics frameworks is also addressed. Despite substantial progress, challenges related to data privacy, algorithm transparency, clinical validation, regulatory compliance, infrastructure requirements, and healthcare accessibility remain significant barriers to widespread implementation. Future innovations such as digital twins, federated learning, quantum computing, and advanced nanorobotics are expected to further advance precision oncology. Collectively, smart biomedical technologies are reshaping cancer care and paving the way toward more predictive, personalized, and patient-centred oncology practice.

KEYWORDS: Precision oncology; Smart biomedical technologies; Artificial intelligence; Cancer diagnostics; Personalized therapeutics.

1. INTRODUCTION
1.1 Global Burden of Cancer and the Need for Precision Oncology
Cancer is a significant public health problem worldwide, and it is on the increase both in terms of incidence and mortality, posing substantial burden on health care systems. Tumors are heterogeneous, and often patient responses to traditional approaches to treatment are variable. Consequently, precision oncology has emerged as a promising strategy that tailor's diagnosis and treatment according to the molecular and genetic characteristics of individual patients (1) Precision medicine combines biomarker analysis and molecular profiling for more precise patient stratification and targeted therapeutic interventions, leading to better treatment outcomes and minimizing unnecessary toxicity (2). These are the developments in cancer care that are helping to create personalized treatment strategies (3,4).

1.2 Evolution of Smart Biomedical Technologies in Oncology
Precision oncology has recently been quickly adopted thanks to recent advancements in smart biomedical technologies. AI advancements in artificial intelligence, biosensors, wearable technologies, high-tech imaging, and digital health platforms have paved the way for real-time patient information collection and analysis, allowing for early detection and precision health management. The new technologies enable the shift from the traditional reactive healthcare to a more predictive and patient-focused approach (5). In addition, advancements in biomedical engineering have helped the design of more advanced diagnostic and monitoring systems for cancer diagnosis, which increase the accuracy and efficiency of cancer detection and treatment planning (6,7).

1.3 Scope and Objectives of the Review

The use of genomics, bioinformatics, artificial intelligence and molecular diagnostics has resulted in new possibilities in the field of personalized cancer management. These enabling technologies facilitate discovery of biomarkers, treatment selection, monitoring of diseases and clinical decision making, and thus are at the heart of precision oncology today. Furthermore, improved molecular medicine, targeted treatments and smart healthcare systems keep introducing new possibilities for technology-based personalized treatment approaches. An overview of the smart biomedical technologies and their applications in precision oncology related to cancer diagnosis, disease monitoring and personalized therapeutics is presented here. Additionally, the challenges and innovations in the field, along with prospects, are explored, highlighting the evolving landscape of precision cancer care.

2. Smart Biomedical Technologies: Foundations and Principles

2.1 Concept and Classification of Smart Biomedical Technologies

Smart Biomedical technologies include a wide variety of advanced tools and systems that combine biomedical sciences with digital technologies to enhance the diagnosis, monitoring and treatment of diseases. These include Artificial intelligence (AI), Biosensors, Wearable devices, Internet of Things (IoT) platforms, Advanced imaging systems, Nanotechnology based devices and Computational analytics. In oncology, smart biomedical technology can help collect, process, and interpret complex biological and clinical information to make more precise and individualized health-care interventions. With the advent of multimodal AI, biomedical engineering, and data-driven healthcare systems, cancer detection, characterization, and management capabilities across different stages of disease progression have been significantly boosted (8).

2.2 Integration of Artificial Intelligence, IoT, and Big Data in Oncology

AI, IoT and biomedical big data are essential for precision oncology's successful implementation. The combination of AI algorithms and extensive datasets (genomic, imaging, clinical etc.) can help identify disease patterns, predict treatment outcomes, and aid in clinical decision making. At the same time, IoT-powered medical devices and health care systems enable constant capture of patient information and real-time monitoring and custom interventions. With the advent of biomedical big data, there is now a chance to leverage these high volumes of data with advanced analytics and predictive modelling, which can help healthcare providers extract meaningful insights from various data sources. These technologies, combined with others, enable more efficient, accurate and patient-centric cancer management strategies (9,10).

2.3 Digital Health Ecosystems for Precision Cancer Care

Digital health ecosystems are playing an important role in modern precision oncology, allowing for the seamless interactions between patients, healthcare providers, diagnostic systems and therapeutic systems. These systems encompass the use of electronic health records, cloud computing, AI-powered data analysis, remote monitoring systems, and smart healthcare infrastructures. These inter-connected systems allow immediate access to patient information, help coordinate care, and aid in evidence-based clinical decision making. Moreover, Industry 4.0 technologies such as automation, machine learning, and intelligent data exchange have drastically hastened the shift to personalized and digitally enabled cancer pathways (11).

2.4 Role of Biomarkers and Multi-Omics Technologies

The backbone of precision oncology is the investigation of detailed molecular features of tumors, through biomarkers and multi-omics technologies. The identification of predictive and prognostic biomarkers for disease diagnosis, risk assessment, treatment choice and disease monitoring is now possible with advances in genomics, transcriptomics, proteomics, metabolomics and epigenomics. By using biomarkers to stratify patients based on molecular profiles, therapy selection is more precise and effective. Recent advances in the discovery of cancer biomarkers, along with multi-omics comprehensive analyses, have greatly helped in comprehending tumor biology and disease heterogeneity (12). Furthermore, combining the use of omics technologies with targeted therapies and intelligent biomedical platforms has reinforced the personalized approach in oncology research, notably in the context of complex cancers like colorectal cancer (13). The major smart biomedical technologies currently supporting precision oncology and their respective applications are summarized in Table 1. The major components of smart biomedical technologies and their interconnections within precision oncology are illustrated in Figure 1.

Table 1. Major Smart Biomedical Technologies and Their Roles in Precision Oncology

Technology	Principle	Major Oncology Applications	Advantages	References
Artificial Intelligence	Data-driven predictive analytics	Diagnosis, prognosis, treatment selection	High accuracy and automation	(14)
Biosensors	Detection of cancer biomarkers	Early diagnosis and monitoring	Rapid and sensitive detection	(15,16)
Wearable Devices	Continuous physiological monitoring	Remote patient surveillance	Real-time monitoring	(17)
Nanotechnology	Nanoscale diagnostic and therapeutic systems	Cancer detection and targeted therapy	Enhanced specificity	(18,19)

Multi-omics Technologies	Comprehensive molecular profiling	Biomarker discovery and patient stratification	Personalized treatment planning	(12)
Digital Health Platforms	Integrated patient data management	Clinical decision support	Improved healthcare coordination	(11)



Figure 1. Framework of Smart Biomedical Technologies in Precision Oncology

3. Advanced Technologies for Cancer Diagnosis

3.1 AI-Assisted Medical Imaging and Radiomics

AI systems have made substantial contributions to cancer diagnosis by accurately and efficiently analysing large and complex datasets in medical imaging. AI algorithms, specifically deep learning models, have the potential to identify more subtle imaging characteristics that might not be noticed during traditional analysis, enhancing the early detection of cancer, tumor classification, and prognosis evaluation. Radiomics further expands this ability to the extraction of quantitative imaging biomarkers from imaging modalities like computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET). These practices are used for precision oncology, enabling precision diagnostic and therapeutic decision making. Recent advances have also shown the potential of AI to enhance diagnostic outcomes in various types of cancers, such as neuro-oncology and solid tumors (14,20).

3.2 Biosensors and Smart Diagnostic Platforms

Biosensors are becoming powerful tools for fast, sensitive and less-invasive detection of cancer. The modern biosensor platforms combine the biological recognition element with high level signal processing systems that detect biomarkers associated with cancer in blood, saliva, urine and tissue samples. Recent developments have enhanced the sensitivity, specificity and portability of biosensors to be used in point of care diagnostics and personalized health care (16). Moreover, the smart diagnostic platforms using a combination of biosensors and digital analytics, and molecular informatics are enabling earlier diagnosis and real-time assessment of disease. These will revolutionise cancer diagnostics offering cost-effective and accessible solutions to be used in clinical practice (15,21).

3.3 Liquid Biopsy Technologies for Early Cancer Detection

Currently, liquid biopsy is a promising alternative to traditional tissue biopsy as it allows the non-invasive detection of circulating tumor cells, circulating tumor DNA, extracellular vesicles, and other tumor-derived biomarkers. The use of these technologies not only enables the assessment of tumor heterogeneity and molecular evolution but also lowers the risks of invasive sampling. Liquid biopsy is emerging as a powerful tool in the early detection, monitoring and selection of therapies in CRC and other types of cancer. Liquid biopsy combined with other cutting-edge molecular technologies is likely to enhance precision oncology applications further (22).

3.4 Genomic, Proteomic, and Metabolomic Profiling

Cancer diagnostics is entering a new era, with multi-omics profiling serving as a backbone to gain insights into the biology of the tumor. While genomic analysis allows the detection of mutations, copy number variations and genetic changes associated with carcinogenesis, proteomic and metabolomic analysis give insight into functional changes associated with disease progression. Combining these data allows the identification of molecular signatures that can be useful for risk stratification, biomarker discovery and therapeutic targeting. The growing understanding of the intricacies of genomics and the advent of AI have also enhanced the interpretation of complex omics data, guiding more precise and individualized diagnostic strategies (23).

3.5 Nanotechnology-Based Diagnostic Approaches

One of the new possibilities for diagnosis afforded by nanotechnology is the design of nanoscale materials that detect cancer biomarkers with great sensitivity. The use of nanoparticles, quantum dots, nanowires, and nanostructured biosensors increases the signal amplification and molecular recognition, which aids in early and proper diagnosis. These technologies also enable the multimodal imaging and the targeted detection of biomarkers, thereby enhancing diagnostic accuracy of different types of cancers. The applications of nanotechnology-based biomedical devices and engineered nanoparticles in cancer diagnostics and personalized medicine are continually growing in recent research.

3.6 Point-of-Care Diagnostic Systems

Rapid and decentralized testing by point-of-care diagnostic systems is revolutionizing cancer detection. The platforms include portable analytical devices, microfluidic technologies and companion diagnostics, and provide clinical information at the right time without extensive laboratory infrastructure. The use of biotechnology, AI, and molecular diagnostics in point-of-care systems can aid in delivering personalized healthcare, as well as facilitating quick and effective clinical decision-making and patient management. These innovations are especially useful for resource-constrained areas and remote healthcare environments (24).

3.7 Digital Pathology and Computational Histopathology

The use of computational analysis techniques and the digitization of histopathological slides have transformed cancer diagnostics via digital pathology. AI-based histopathology systems can automatically detect malignant cells, categorize tumor sub-types, and quantify pathological features in a reproducible fashion. These technologies increase accuracy of diagnosis, decrease observer variability, and increase workflow efficiency in the pathology lab. The increasing use of AI in the field of pathology is a major step towards precision oncology and personalized cancer diagnosis (25).

3.8 Emerging Diagnostic Innovations and Clinical Applications

Precision oncology is continually growing, with the emergence of new diagnostic technologies driving capabilities. New tools that are combining advanced analytical techniques, theranostic platforms, optical imaging systems and AI-enhanced diagnostic tools are helping to detect and characterize cancer at ever-earlier stages. The technology that incorporates optical coherence tomography (OCT) with nanoparticles and artificial intelligence has great potential for the imaging of tumors at high resolution and their real-time clinical assessment. Likewise, novel analytical methods are making it possible to comprehensively characterize and manage disease at the molecular level. These advancements, together, are driving the future of cancer diagnostics and hastening the adoption of precision medicine in clinical oncology (26,27). A comparative overview of emerging diagnostic technologies and their clinical significance in cancer detection is provided in Table 2. The principal technologies currently employed for advanced cancer diagnosis are summarized in Figure 2.

Table 2. Emerging Technologies for Cancer Diagnosis in Precision Oncology

Technology	Diagnostic Function	Clinical Significance	References
AI-Assisted Imaging	Tumor detection and classification	Improves diagnostic accuracy	(14)
Radiomics	Quantitative image analysis	Predicts disease characteristics	(20)
Biosensor Platforms	Biomarker detection	Early cancer diagnosis	(16)
Liquid Biopsy	ctDNA and circulating biomarkers	Non-invasive tumor profiling	(22)
Multi-Omics Profiling	Molecular characterization	Precision diagnostics	(23)
OCT-Based Imaging	High-resolution tumor imaging	Real-time visualization	(27)
Nanodiagnostics	Enhanced biomarker detection	High sensitivity screening	(19)
Digital Pathology	AI-based histopathology analysis	Improved pathological assessment	(25)



Figure 2. Advanced Technologies for Cancer Diagnosis

4. Smart Technologies for Cancer Monitoring and Disease Surveillance

4.1 Wearable Sensors and Remote Patient Monitoring

In the last few years, wearable technologies have become a useful tool for continuous monitoring of cancer patients outside the traditional clinical environment. These intelligent devices can measure physiological factors like heart rate, activity, sleep habits, body temp, treatment-related symptoms, in real time. Wearable sensors for use in oncology practice allow for remote patient monitoring, earlier detection of complications, and a better understanding of tolerability to treatment. Additionally, wearable technology has shown great promise to support decentralized clinical trials and enable patient centred cancer care by offering a constant feed of clinically relevant data (17).

4.2 Continuous Physiological Monitoring Systems

The invention of continuous physiological monitoring systems based upon the new sensor and microelectronics technologies has made it possible to monitor the dynamics of patient health status. Smart sensors can track respiratory function, oxygen saturation, cardiovascular activity, and other physiologic metrics that can measure a patient's disease state or response to therapy. These technologies are now being integrated into precision medicine for the oncology field for longitudinal monitoring and personalized disease management. These systems are especially beneficial for patients who might need continuous monitoring during treatment and recovery periods, especially those considered high-risk.

4.3 Circulating Tumor DNA (ctDNA) and Biomarker Tracking

Monitoring circulating tumor DNA (ctDNA) and other molecular markers has emerged as an essential pillar to precision oncology. Biomarker tracking can help clinicians monitor tumor dynamics, minimal residual disease, emerging therapeutic resistance, as well as the effectiveness of treatment. These capabilities are further expanded by emerging theranostic technologies – which merge diagnostics and therapeutics in integrated platforms. These methods enable more precise disease monitoring and help in delivering prompt clinical interventions informed by real-time molecular data (28).

4.4 Digital Biomarkers in Oncology

Digital biomarkers are objective and quantifiable measurements, such as physiological or behavioural, that are taken by connected devices, sensors, and digital health platforms. These biomarkers give a continuous stream of information about patient status, treatment response and progression of the disease. Digital biomarkers have gained in sensitivity and precision and now have the capability to be used in real-time analytical applications thanks to the incorporation of nanotechnology powered AI sensors. The use of such technologies is gaining traction in the field of monitoring tumor progression and providing personalized oncological care (29).

4.5 AI-Based Prediction of Disease Progression

Analysis of multimodal clinical, genomic, imaging and biomarker data has made Artificial Intelligence (AI) an effective tool to predict disease progression. The goal is for machine learning algorithms to detect patterns that are correlated with tumor evolution, recurrence risk and treatment outcomes which may not be immediately obvious in traditional analytical techniques. These predictive features enable physicians to forecast disease progression, fine-tune therapies, and adopt proactive measures based on patient characteristics. AI is thus increasingly becoming part of precision oncology systems (30).

4.6 Monitoring Treatment Response Through Smart Platforms

Evaluation of treatment response is crucial to ascertain the efficacy of treatment and to inform future management. Patient outcomes and changes in patient health related to treatment can be continuously assessed using smart monitoring platforms that incorporate AI, digital health technologies, and advanced analytics. These can handle large amount of clinical and molecular data to find out response patterns and evidence-based adjustment of treatment. Smart platforms enable therapeutic monitoring, aiding in personalized and adaptive cancer management strategies, in real time (31).

4.7 Tele-Oncology and Virtual Care Models

Tele-oncology has emerged as a rapidly growing method to access specialized cancer care and decrease geographical and logistical obstacles. Virtual care platforms can be used to make remote consultations, monitor treatment, educate patients, and conduct follow-up assessments via secure digital communication systems. The integration of AI-powered precision healthcare technologies further enhances tele-oncology by supporting data-driven clinical decision-making and personalized patient management. They have enhanced the continuity of care and bolstered precision oncology care across a variety of health care environments (32).

4.8 Real-Time Data Analytics for Clinical Decision Support

The real-time data that is generated from cancer monitoring has proven to be an integral part of smart cancer monitoring systems that can be converted into clinical insights and actions. Advanced analytical frameworks are in place that combine data from wearable technologies, molecular diagnostics, imaging systems and electronic health records to enable timely decision-making. Biotechnology-driven companion diagnostics, combined with artificial intelligence, further improve clinical evaluations for greater accuracy and efficiency. Real-time analytics can help to enhance the understanding of complex datasets, improve disease surveillance, and optimize personalized treatment in precision oncology (24). The major smart technologies used for cancer monitoring and disease surveillance are summarized in Table 3. An overview of the smart cancer monitoring ecosystem, including wearable devices, biomarkers, and clinical decision-support systems, is presented in Figure 3.

Table 3. Smart Technologies for Cancer Monitoring and Disease Surveillance

Technology	Monitoring Parameter	Clinical Utility	References
Wearable Sensors	Vital signs and activity levels	Remote monitoring	(17)
Smart Sensors	Physiological biomarkers	Continuous assessment	(33)
ctDNA Monitoring	Tumor burden and recurrence	Disease surveillance	(28)
Digital Biomarkers	Behavioral and physiological data	Personalized monitoring	(29)
AI Predictive Systems	Disease progression patterns	Prognostic prediction	(30)
Tele-Oncology Platforms	Patient follow-up	Improved accessibility	(32)
Clinical Decision Analytics	Real-time treatment monitoring	Adaptive treatment planning	(24)



Figure 3. Smart Cancer Monitoring Ecosystem

5. Personalized Therapeutics Enabled by Smart Biomedical Technologies

5.1 Precision Medicine and Personalized Treatment Planning

Precision Medicine has revolutionized cancer treatment by moving from generic therapeutic strategies to individual cancer care approaches tailored to the molecular and clinical features of each patient. Increasing knowledge about genomics, biomarkers, and molecular diagnostics has given doctors more options to choose a therapy that is more likely to have a positive result, while reducing unwanted side effects. This patient-centred approach has boosted treatment effectiveness and helped in the development of personalized therapeutic regimens for different types of cancer (34).

5.2 AI-Guided Drug Selection and Therapeutic Optimization

AI is now increasingly being used to harness vast amounts of information from genomics, imaging, pathology, and medical records to guide therapeutic decision-making. AI-powered systems can detect treatment-response patterns, forecast drug sensitivity and facilitate personalized selection of treatments. Additionally, research in genomics has led to the creation of personalized therapeutic approaches, enhancing the precision of treatment and patient outcomes. The latter developments are helping to facilitate improved, personalized cancer care (35).w

5.3 Smart Drug Delivery Systems and Nanomedicine

Smart drug delivery technologies have become key to boost cancer therapeutics specificity and efficiency. The use of nanoelectronics drug delivery systems and other sophisticated nanomedicine platforms facilitates the controlled and targeted delivery of therapeutic agents directly into tumor sites, where treatments are more effective and toxicity is minimized in the rest of the body. These technologies are suitable to respond to biological stimuli, regulate drug release, and enhance the pharmacokinetic performance, making them highly suitable for precision oncology applications (36).

5.4 Targeted Therapy and Immunotherapy Applications

The development and use of targeted therapies and immunotherapies have transformed cancer treatment strategies, with an emphasis on targeting the molecular pathways and immune mechanisms underlying cancer development and progression. New developments in precision genomics, immuno-engineering and modulation of the tumor microenvironment have enabled the generation of new generation therapeutic strategies that can overcome complicated oncological problems. The use of such strategies provides greater specificity and clinical efficacy and can also help enable personalized treatment paradigms (37).

5.5 Gene Editing and CRISPR-Based Therapeutics

The field of personalized oncology has a promising future with gene-editing technologies, especially those based on CRISPR. These methods offer powerful tools to manipulate genetic changes associated with disease and have significant potential for the correction of oncogenic mutations, for improving immune cell function and for improving therapeutic outcomes. With the progression of molecular medicine and personalized drug development, the use of gene-editing technologies has come into the limelight as a novel approach for future cancer treatment strategies (4).

5.6 Digital Twins in Personalized Cancer Treatment

Digital twin technology is the technology used to create virtual patients that mimic biological, molecular, and clinical data in a computational setting. These models can be used to simulate disease progress, predict treatment responses and assess therapeutic interventions prior to clinical application. New sustainable biomedical technologies and powerful computational systems are enabling the growth of digital twins and potentially making them relevant for the optimization of personalized treatment plans and precision oncology outcomes (38).

5.7 Predictive Models for Therapeutic Response

Predictive modelling is increasingly a key part of personalized therapeutics, to predict therapeutic response, tailored to individual patients. AI-driven precision healthcare leverages genomic, clinical, and biomarker data to target patients most likely to respond to therapeutic interventions. These predictive strategies promote evidence-based treatment choices, minimize trial-and-error treatment and have the potential to support more effective cancer management strategies (32).

5.8 Case Studies of Personalized Oncology Interventions

Personalized oncology is only possible with engineering innovations, molecular diagnostics, computational analytics and targeted therapies. Precision medicine strategies have been successfully applied to a variety of clinical applications for optimizing therapeutic outcomes, treatment selection and monitoring. The development of smart biomedical systems in cancer care is still evolving and continues to bring practical examples of precision medicine, indicating the transformative potential of smart biomedical systems in modern cancer care (7). Key smart biomedical technologies facilitating personalized cancer therapeutics and their clinical benefits are presented in Table 4. The integration of molecular profiling, artificial intelligence, and targeted interventions in personalized therapeutics is illustrated in Figure 4.

Table 4. Smart Biomedical Technologies Supporting Personalized Cancer Therapeutics

Technology	Therapeutic Application	Clinical Benefit	References
Genomic-Guided Therapy	Personalized treatment selection	Improved efficacy	(34)
AI-Based Drug Selection	Therapy optimization	Better treatment outcomes	(35)
Smart Drug Delivery Systems	Controlled drug release	Reduced toxicity	(36)
Targeted Therapies	Molecular pathway inhibition	Enhanced precision	(37)
Gene Editing Technologies	Mutation correction	Potential curative applications	(4)
Digital Twins	Virtual treatment simulation	Personalized treatment planning	(38)
Predictive AI Models	Therapeutic response prediction	Precision intervention	(32)



Figure 4. Personalized Therapeutics Enabled by Smart Biomedical Technologies

6. Integration of Smart Biomedical Technologies into Clinical Oncology Practice

6.1 Clinical Decision Support Systems

Precision oncology relies on the use of clinical decision support systems (CDSSs) to help health care providers understand complex clinical, molecular, and genomic information. These systems combine patient-specific information with evidence-based knowledge to aid diagnosis, treatment choices and therapeutic monitoring. Incorporation of companion diagnostics, molecular biomarkers, and AI has boosted the precision and efficacy of clinical decision-making, leading to more personalized treatment approaches and better patient outcomes (24).

6.2 Electronic Health Records and Interoperability

Seamless communication of patient data among systems is a key to effective precision oncology. Electronic health records (EHRs) are a central repository for clinical, diagnostic and therapeutic data which is helpful in complete management of patient. With the advances of Industry 4.0 technologies, the level of interoperability has been further enhanced with intelligent data sharing, automation, and real-time communication among healthcare stakeholders. All these advancements provide the infrastructure for coordinated care delivery and drive the effective implementation of precision medicine in clinical practice (11).

6.3 Multi-Omics Data Integration Frameworks

With the advent of genomic, transcriptomic, proteomic, metabolomic and epigenomic data, there is a chance for a complete characterization of cancer biology. Incorporating multi-omics data through integration frameworks empowers clinicians and researchers to leverage a variety of molecular data to reveal insights into disease mechanisms, identify biomarkers, and inform personalized therapeutic strategies. These strategies are especially useful in the context of complex malignancies, where molecular heterogeneity can greatly impact treatment response and clinical outcomes (13).

6.4 AI-Assisted Precision Oncology Workflows

In recent years, AI has emerged as a pivotal force in the field of oncology, aiding in the analysis of data, prediction modelling, treatment planning, and patient monitoring. Healthcare platforms that incorporate AI can analyse vast amounts of clinical and molecular data, assisting healthcare professionals in determining the best course of action for treatment and predicting the course of a disease. AI's incorporation into oncology workflows optimizes efficiency, boosts the precision of diagnostics, and aids in evidence-based personalized treatment choices, strengthening the delivery of precision cancer care (32).

6.5 Hospital-Based Smart Oncology Platforms

The emergence of a smart oncology platform in the hospital has made it easier to integrate cutting-edge biomedical technologies into the normal clinical setting. These systems integrate artificial intelligence, digital health systems, molecular diagnostics, imaging technology and patient monitoring devices in a single system. In this context, multimodal AI systems are especially useful as they can process various types of biomedical data, providing insights relevant to the clinical context and aiding in personalized diagnosis and treatment planning. These kinds of integrated platforms are supporting healthcare institutions to progress to more information-driven and patient-centric oncology services (8).

6.6 Regulatory and Clinical Validation Requirements

As fast as smart biomedical technologies are improving, a more rigorous validation and regulatory control are needed for their successful application in the clinic. Precision oncology technologies will have to be shown to be safe, reliable, reproducible, and clinically useful before being implemented broadly. To ensure emerging technologies deliver meaningful benefits to patients, it is important to have standardized validation protocols, regulatory frameworks, and evidence-based assessments. Moreover, as genomic and digital health technologies become more complex, it is important to have strong governance structures to enable their responsible use in health services (6).

6.7 Cost-Effectiveness and Healthcare Accessibility

Economic factors are important factors in precision oncology technology uptake and viability. Although these smart biomedical innovations have the potential to enhance patient outcomes and cut long-term healthcare costs, they will likely necessitate significant investments in infrastructure, training and technological resources. It is difficult to reach equitable access to these innovations, especially in low resource environments. Precision medicine models highlight a need to reconcile the technological progress with affordability and accessibility, so that precision medicine benefits can be applied to a variety of patient populations (5).

6.8 Real-World Clinical Implementations

The translation of smart biomedical technologies in the context of research to clinical reality has proven the feasibility and efficacy of precision oncology in health care. Biomarker-driven treatments, molecular diagnostics, AI to support decision making and personalized treatment planning have all demonstrated a great deal of promise in terms of influencing clinical outcomes. With the ongoing adoption of precision medicine principles in the healthcare system, the use of real-world evidence to support the integration of these technologies into the traditional oncology care pathway is becoming more important, which further enhances the importance of these technologies as a key contributor to advancing personalized cancer management (2).

7. Challenges, Ethical Considerations, and Limitations

7.1 Technical and Validation Challenges

Although great progress has been made on the implementation of smart biomedical technologies in precision oncology, there remain technical challenges to address. Large biomedical datasets can be challenging to manage, with concerns about data security and privacy, and the need to integrate data from various sources can impact interoperability and system performance (9). Furthermore, AI-based diagnostic and monitoring systems can be subject to algorithm bias and lack in explanations, which can impact clinical trust and decision-making (20). In addition, there is a lack of standardized validation frameworks and consistent performance evaluation for the widespread adoption of emerging technologies in the practice of oncology (26).

7.2 Regulatory, Legal, and Infrastructure Barriers

Smart biomedical technologies need strong regulation and law to ensure their clinical translation. Data ownership and informed consent challenges, clinical accountability, and regulatory approval are still outstanding issues. Additionally, the adoption of such advanced precision oncology systems can be resource-intensive, demanding significant investments in digital infrastructure, computational resources, and specialized expertise, which can be challenging for healthcare institutions with limited resources (11).

7.3 Equity, Accessibility, and Ethical Concerns

Despite the promise of precision oncology, advanced diagnostics, genomic testing and targeted therapy are not equally available globally and limit the impact of precision oncology. Socio-economic and geographic inequities may limit access to innovative technologies and personalized treatment options (1). The use of AI in cancer care also raises ethical issues, like transparency, fairness, patient autonomy, and accountability for AI-driven clinical decisions (25).

7.4 Limitations and Future Considerations

Despite the progress of current smart biomedical technologies, they are still hampered by complex technologies, high cost of implementation, incomplete datasets and lack of interoperability across healthcare systems. These constraints can make them less effective in being integrated in standard clinical practice and less scalable to different healthcare environments (31). To achieve the best long-term results of precision oncology with smart biomedical technologies, it will be essential to address challenges related to improved validation, ethical governance, regulatory harmonization, and equitable access.

8. Future Perspectives and Emerging Trends

8.1 Intelligent and Connected Oncology Technologies

The next generation of biosensors, wearables and digital health platforms that can continuously track patient health and tumor associated biomarkers will be a key part of future precision oncology. These technologies will enhance early disease detection, surveillance, and personalized clinical decision making, with real-time data collection and integrated healthcare systems.

8.2 Advanced Computational Models and Artificial Intelligence

New technologies like digital twins, federated learning and decentralized AI can revolutionize the personalization of cancer care. Virtual patient models could help to simulate disease progression and treatment outcomes, and privacy-preserving AI frameworks could allow for collaborative research and enhance the accuracy of predictions without compromising patient privacy (39).

8.3 Emerging Therapeutic and Analytical Innovations

Precision oncology is expected to be further advanced by further development in the areas of quantum computing, nanorobotics and integrated multi-omics analytics. These innovations could speed up the discovery of biomarkers, thus better matching patients with the most appropriate therapeutic options, better targeted drug delivery, and give insights into the biology of cancer, ultimately aiding increasingly personalized treatment strategies.

AI, high-resolution diagnostics, digital health, and personalized therapy will most probably exist simultaneously as part of a single healthcare system in the future of oncology. This integration will facilitate predictive, preventive, personalized and patient-centred use of cancer therapeutics to manage the disease better and improve clinical outcomes. With the ongoing development of these technologies, smart biomedical systems are poised to contribute more to precision oncology in the future. The major challenges, limitations, and future opportunities associated with smart biomedical technologies in precision oncology are outlined in Table 5.

Table 5. Challenges and Future Directions of Smart Biomedical Technologies in Precision Oncology

Domain	Major Challenges	Future Opportunities	References
Data Management	Privacy and cybersecurity concerns	Secure federated learning systems	(9)
Artificial Intelligence	Algorithm bias and explainability	Transparent and interpretable AI	(20)
Clinical Validation	Lack of standardization	Robust validation frameworks	(26)
Regulatory Issues	Legal and ethical concerns	Harmonized regulations	(6)
Infrastructure	High implementation costs	Industry 4.0 healthcare integration	(11)
Accessibility	Unequal access to precision medicine	Broader healthcare inclusion	(1)
Ethical Concerns	AI-driven decision-making	Responsible AI governance	(25)
Technology Limitations	Interoperability and scalability issues	Advanced integrated platforms	(31)

9. CONCLUSION

With the advent of smart biomedical technologies, precision oncology has been revolutionized to provide more accurate diagnosis, constant monitoring of the disease and personalized therapeutic intervention. New technologies in cancer care, such as AI, biosensors, wearables, multi-omics, nanomedicine and digital health platforms, have moved cancer care away from traditional, one-size-fits-all solutions toward personalised, data-driven treatment options. Sophisticated diagnostic tools such as AI empowered imaging, liquid biopsy, molecular profiling and smart biosensors have led to improved early cancer detection and characterization of tumors. Real-time monitoring systems and digital health technologies, in turn, enable the continuous evaluation of the progression of the disease and the patients' response to treatment, resulting in timely clinical decisions. In the field of therapeutics, advancements like targeted drug delivery systems, immunotherapies, gene-editing techniques and predictive analytics have improved the precision of drug treatment and minimized side effects. However, there are still several obstacles to be overcome, such as concerns about data privacy, algorithmic bias, regulatory complexities, the cost of implementation, and access inequities in healthcare. To ensure the safe, ethical and fair use of smart biomedical technologies in oncology practice, these issues need to be addressed. Precision oncology is likely to be further bolstered by future advancements in the areas of digital twins, federated learning, quantum computing, novel nanotechnologies and integrated multi-omics analytics. As these innovations further develop, smart biomedical technologies will increasingly be part of the equation in delivering predictive, personalized and patient-centred cancer care, helping to improve clinical outcomes and propel the future of oncology.

REFERENCES

1. Mahmood AAR, Jha AM, Manivannan K. Precision medicine: personalizing the fight against cancer. International Journal of Trends in OncoScience. 2024;10–8.
2. Geanta M, Boata A, Brand A, Cucos B, Lehrach H. Precision Medicine in Oncology and Cancer Therapeutics. In: Hasanzad M, editor. Precision Medicine in Clinical Practice [Internet]. Singapore: Springer Nature Singapore; 2022 [cited 2026 Jun 19]. p. 33–51. Available from: https://link.springer.com/10.1007/978-981-19-5082-7_3 doi:10.1007/978-981-19-5082-7_3
3. Rituraj, Pal RS, Wahlang J, Pal Y, Chaitanya M, Saxena S. Precision oncology: transforming cancer care through personalized medicine. Med Oncol. 2025 Jun 9;42(7):246. doi:10.1007/s12032-025-02817-y
4. Sobti RC, Wilson DW, Buttar HS, Telessy IG, Sobti A. Molecular Medicine and Biomedical Research in the Era of Precision Medicine: New Technologies and Personalized Drug Therapies for Patient Care [Internet]. Elsevier; 2025 [cited 2026 Jun 19]. Available from: https://books.google.com/books?hl=en&lr=&id=dnEmEQAAQBAJ&oi=fnd&pg=PP1&dq=Smart+Biomedical+Technologies+for+Precision+Oncology:+Advancements+in+Cancer+Diagnosis,+Monitoring,+and+Personalized+Therapeutics)&ots=m3dJVdQTwk&sig=UAOKRAtdEK9FGAMVWvtmhEazqOw
5. Seyhan AA, Carini C. Are innovation and new technologies in precision medicine paving a new era in patients centric care? J Transl Med. 2019 Dec;17(1):114. doi:10.1186/s12967-019-1864-9
6. Ho D, Quake SR, McCabe ER, Chng WJ, Chow EK, Ding X, et al. Enabling technologies for personalized and precision medicine. Trends in biotechnology. 2020;38(5):497–518.
7. Sun W, Lee J, Zhang S, Benyshek C, Dokmeci MR, Khademhosseini A. Engineering Precision Medicine. Advanced Science. 2019 Jan;6(1):1801039. doi:10.1002/advs.201801039
8. Parvin N, Joo SW, Jung JH, Mandal TK. Multimodal AI in biomedicine: pioneering the future of biomaterials, diagnostics, and personalized healthcare. Nanomaterials. 2025;15(12):895.
9. Yang X, Huang K, Yang D, Zhao W, Zhou X. Biomedical Big Data Technologies, Applications, and Challenges for Precision Medicine: A Review. Global Challenges. 2024 Jan;8(1):2300163. doi:10.1002/gch2.202300163
10. Vinchurkar K, Polshettiwar S, Dargude S. Internet of Things and precision medicine: tailoring treatments to individual patients. In: Connected Diagnoses [Internet]. Elsevier; 2026 [cited 2026 Jun 19]. p. 1–27. Available from: https://www.sciencedirect.com/science/chapter/edited-volume/pii/B9780443382994000126
11. Waaje A, Karim R, Roshid MM, Yeamin B, Meem TN. Integration of industry 4.0 with personalized medicine: A shift of the paradigm in healthcare. In: AI-driven personalized healthcare solutions [Internet]. IGI Global Scientific Publishing; 2025 [cited 2026 Jun 19]. p. 27–70. Available from: https://www.igi-global.com/chapter/integration-of-industry-40-with-personalized-medicine/371213
12. AlDoughaim M, AlSuhebany N, AlZahrani M, AlQahtani T, AlGhamdi S, Badreldin H, et al. Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations. Clin Med Insights Oncol. 2024 Jan;18:11795549241298541. doi:10.1177/11795549241298541
13. Addissouky TA. Next generation of colorectal cancer management: integrating omics, targeted therapies, and smart technologies. Avicenna Journal of Medical Biochemistry. 2024;12(2):131–43.
14. Tiwari A, Mishra S, Kuo TR. Current AI technologies in cancer diagnostics and treatment. Mol Cancer. 2025 Jun 2;24(1):159. doi:10.1186/s12943-025-02369-9
15. Hemdan M, Ali MA, Doghish AS, Mageed SSA, Elazab IM, Khalil MM, et al. Innovations in biosensor technologies for healthcare diagnostics and therapeutic drug monitoring: applications, recent progress, and future research challenges. Sensors. 2024;24(16):5143.
16. Raza A, Zulfiqar H, Gong Z, Chen Y, Chen Y. A comprehensive review on biomedical sensors: technological advancements, applications in molecular informatics, and future trends [Internet]. 2024 [cited 2026 Jun 19]. Available from: https://www.preprints.org/frontend/manuscript/f3bb6f76a2e7243759a48af05090af1a/download_pub
17. Beg S, Handa M, Shukla R, Rahman M, Almalki WH, Afzal O, et al. Wearable smart devices in cancer diagnosis and remote clinical trial monitoring: Transforming the healthcare applications. Drug discovery today. 2022;27(10):103314.
18. Kiani MN, Khaliq H, Abubakar M, Rafique M, Jalilov F, Ashraf GA, et al. Advancing the potential of nanoparticles for cancer detection and precision therapeutics. Med Oncol. 2025 Jun 4;42(7):239. doi:10.1007/s12032-025-02782-6
19. Tantray J, Patel A, Parveen H, Prajapati B, Prajapati J. Nanotechnology-based biomedical devices in the cancer diagnostics and therapy. Med Oncol. 2025 Jan 20;42(2):50. doi:10.1007/s12032-025-02602-x
20. Khalighi S, Reddy K, Midya A, Pandav KB, Madabhushi A, Abedalthagafi M. Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment. NPJ precision oncology. 2024;8(1):80.
21. Olatunji GI, Ajayi OO, Ezeh FE. A Hybrid Engineering-Medicine Paradigm for Personalized Oncology Diagnostics Using Biosensor Feedback Systems. Journal not specified [Internet]. 2023 [cited 2026 Jun 19]. Available from: https://shisrrj.com/paper/SHISRRJ236172.pdf
22. Ahluwalia P, Ballur K, Leeman T, Vashisht A, Singh H, Omar N, et al. Incorporating novel technologies in precision oncology for colorectal cancer: advancing personalized medicine. Cancers. 2024;16(3):480.
23. Das S, Mazumder S, Alam N, Vernekar M, Dam A, Bhowmick AK, et al. Precision oncology in the era of genomics and artificial intelligence. Journal of Current Oncological Trends. 2024;1(1):22–30.
24. Sonar P, Mathuvanti KR, Venkataramanan A, Reddy H, Mohanty A. Medical biotechnology and artificial intelligence powered companion diagnostics: indispensable pillars driving next generation precision health care. Biotechnol Lett. 2026 Jun;48(3):58. doi:10.1007/s10529-026-03732-6

25. Selvaraj C, Cho WC, Langeswaran K, Alothaim AS, Vijayakumar R, Jayaprakashvel M, et al. Artificial intelligence in cancer care: revolutionizing diagnosis, treatment, and precision medicine amid emerging challenges and future opportunities. 3 Biotech. 2025 Oct;15(10):355. doi:10.1007/s13205-025-04518-9
26. Gharti L, Kaur SD, Vihal S, Ramakrishna K, Thakur D, Kapoor D, et al. Recent Advances in Analytical Techniques for Cancer Diagnostics and Therapeutics: Combining State-of-the-Art Technologies for Precision Oncology. Critical Reviews in Analytical Chemistry. 2026 Apr 15;1–26. doi:10.1080/10408347.2026.2656439
27. Daneshpour Moghadam S, Maris B, Mokhtari A, Daffara C, Fiorini P. OCT in oncology and precision medicine: from nanoparticles to advanced technologies and AI. Bioengineering. 2025;12(6):650.
28. Ayalew BD, Abdullah, Khan SM, Alemayehu ZG, Teferi MG, Aboye BT, et al. Role of emerging theranostic technologies in precision oncology: revolutionizing cancer diagnosis and treatment. Oncologie. 2025 Mar 26;27(2):229–38. doi:10.1515/oncologie-2024-0543
29. Hota A, Mandal BK. Nanotechnology-Driven AI Sensors: Advancing Precision in Oncotherapy. In: AI Foundations, Technologies, and Future of Healthcare Systems [Internet]. IGI Global Scientific Publishing; 2026 [cited 2026 Jun 19]. p. 349–72. Available from: https://www.igi-global.com/chapter/nanotechnology-driven-ai-sensors/407919
30. Dlamini Z, Hull R. The Application of AI in Precision Oncology: Tailoring Diagnosis, Treatment, and the Monitoring of Disease Progression to the Patient. In: Dlamini Z, editor. Artificial Intelligence and Precision Oncology [Internet]. Cham: Springer Nature Switzerland; 2023 [cited 2026 Jun 19]. p. 1–25. Available from: https://link.springer.com/10.1007/978-3-031-21506-3_1 doi:10.1007/978-3-031-21506-3_1
31. Sherani AMK, Khan M, Qayyum MU, Hussain HK. Synergizing AI and Healthcare: Pioneering advances in cancer medicine for personalized treatment. International Journal of Multidisciplinary Sciences and Arts. 2024;3(2):270–7.
32. Ali KA, Choudhuri S, Chakraborty R, Pradhan A, Kotal A, Shaharyar MA. AI Technology-Powered Precision Medicine and Smart Healthcare: Technical Advancements and Prospects. In: AI and Precision Medicine in Infectious Disease Management [Internet]. CRC Press; 2025 [cited 2026 Jun 19]. p. 51–70. Available from: https://api.taylorfrancis.com/content/chapters/edit/download?identifierName=doi&identifierValue=10.1201/9781003615699-3&type=chapterpdf
33. Stella GM, Lettieri S, Piloni D, Ferrarotti I, Perrotta F, Corsico AG, et al. Smart sensors and microtechnologies in the precision medicine approach against lung cancer. Pharmaceuticals. 2023;16(7):1042.
34. Sharma R, Kannourakis G, Prithviraj P, Ahmed N. Precision medicine: an optimal approach to patient care in renal cell carcinoma. Frontiers in Medicine. 2022;9:766869.
35. Jamalinia M, Weiskirchen R. Advances in personalized medicine: Translating genomic insights into targeted therapies for cancer treatment. Annals of translational medicine. 2025;13(2):18.
36. Eze VHU, Eze CE, Alaneme GU, Mirembe NF, Ugwu OPC, Ogenyi FC, et al. Systematic review of nanoelectronic drug delivery systems advancing technological innovation, clinical integration, and personalized therapy. Frontiers in Nanotechnology. 2026;7:1686599.
37. Alamri AM, Assiri AA, Khan B, Khan NU. Next-generation oncology: integrative therapeutic frontiers at the crossroads of precision genomics, immuno-engineering, and tumor microenvironment modulation. Med Oncol. 2025 Sep 20;42(11):482. doi:10.1007/s12032-025-03042-3
38. Bhadouria AS, Ahirwar A. Future Trends and Emerging Sustainable Technologies in Biomedical Field. In: Advanced Technologies for Sustainable Biomedical Applications [Internet]. CRC Press; 2025 [cited 2026 Jun 19]. p. 445–82. Available from: https://api.taylorfrancis.com/content/chapters/edit/download?identifierName=doi&identifierValue=10.1201/9781003557715-20&type=chapterpdf
39. Gupta V, Kumar D, Gupta S, Tanwar R, Jaiswal N, Islam MM, et al. Nanotechnology-Driven Cancer Therapies for Precision Oncology: Advances and Clinical Outlook. IJN. 2026 Jan;Volume 21:1–33. doi:10.2147/IJN.S568254